Peringatan Keamanan

Osteopenia with extended use, skin necrosis, thrombocytosis, severe immunologically-mediated thrombocytopenia, eosinophilia (rare), calcinosis rarely occurs at the injection site, severe bleeding, transient elevation of liver transaminases.

Nadroparin

DB08813

small molecule approved investigational

Deskripsi

Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) In healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.
Volume Distribusi 3.59L
Klirens (Clearance) The clearance of nadroparin is 21.4 +/- 7.0mL/min

Absorpsi

Absorption is linear. The bioavailability of nadroparin after subcutaneous administration is about 89%.

Metabolisme

Nadroparin is metabolized in the liver.

Rute Eliminasi

Nadroparin is eliminated via the kidneys through non-saturable mechanisms.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

860 Data
Apixaban Apixaban may increase the anticoagulant activities of Nadroparin.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Nadroparin.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Nadroparin.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Nadroparin is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Nadroparin.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Nadroparin.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Nadroparin is combined with Obinutuzumab.
Rivaroxaban Nadroparin may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Nadroparin is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Nadroparin.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Nadroparin.
Urokinase Urokinase may increase the anticoagulant activities of Nadroparin.
Vitamin E Vitamin E may increase the anticoagulant activities of Nadroparin.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Nadroparin.
Trandolaprilat The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Nadroparin.
Moexiprilat The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Nadroparin.
Cilazaprilat The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Nadroparin.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Nadroparin.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Nadroparin.
Quinine The therapeutic efficacy of Nadroparin can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Nadroparin can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Nadroparin.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Nadroparin.
Corticorelin ovine triflutate The risk or severity of hypotension and sinus node depression can be increased when Nadroparin is combined with Corticorelin ovine triflutate.
Oritavancin The therapeutic efficacy of Nadroparin can be decreased when used in combination with Oritavancin.
Streptokinase Streptokinase may increase the anticoagulant activities of Nadroparin.
Telavancin The therapeutic efficacy of Nadroparin can be decreased when used in combination with Telavancin.
Palifermin The serum concentration of Palifermin can be increased when it is combined with Nadroparin.
Pentoxifylline The therapeutic efficacy of Nadroparin can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Nadroparin.
Levocarnitine The therapeutic efficacy of Nadroparin can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Nadroparin.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Nadroparin.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Nadroparin.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Nadroparin.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Nadroparin.
Quinestrol Quinestrol may decrease the anticoagulant activities of Nadroparin.
Hexestrol Hexestrol may decrease the anticoagulant activities of Nadroparin.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Nadroparin.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nadroparin.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Nadroparin.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Nadroparin.
Zeranol Zeranol may decrease the anticoagulant activities of Nadroparin.
Equol Equol may decrease the anticoagulant activities of Nadroparin.
Methallenestril Methallenestril may decrease the anticoagulant activities of Nadroparin.
Epimestrol Epimestrol may decrease the anticoagulant activities of Nadroparin.
Moxestrol Moxestrol may decrease the anticoagulant activities of Nadroparin.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Nadroparin.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Nadroparin.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Nadroparin.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Nadroparin.
Biochanin A Biochanin A may decrease the anticoagulant activities of Nadroparin.
Formononetin Formononetin may decrease the anticoagulant activities of Nadroparin.
Estriol Estriol may decrease the anticoagulant activities of Nadroparin.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Nadroparin.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Nadroparin.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Nadroparin.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Nadroparin.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Nadroparin.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Nadroparin.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Nadroparin.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Nadroparin.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Nadroparin.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Nadroparin.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Nadroparin.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Nadroparin.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Nadroparin.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Nadroparin.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Nadroparin.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Nadroparin.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Nadroparin.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Nadroparin.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Nadroparin.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Nadroparin.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Nadroparin.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Nadroparin.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Nadroparin.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Nadroparin.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Nadroparin.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Nadroparin.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Nadroparin.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Nadroparin.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Nadroparin.
Olsalazine The risk or severity of bleeding can be increased when Nadroparin is combined with Olsalazine.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Nadroparin.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Nadroparin.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Nadroparin.

Target Protein

Antithrombin-III SERPINC1
P-selectin SELP
Protein c-Fos FOS
Myc proto-oncogene protein MYC

Referensi & Sumber

Artikel (PubMed)
  • PMID: 7495071
    Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thebault JJ: Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995 Apr;73(4):630-40.
  • PMID: 8707165
    Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38.
  • PMID: 9158210
    Lai KN, Wang AY, Ho K, Szeto CC, Li M, Wong LK, Yu AW: Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis. 1996 Nov;28(5):721-6.
  • PMID: 9493587
    Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sie P: Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. Thromb Haemost. 1998 Feb;79(2):338-41.
  • PMID: 10210734
    Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H: Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci. 1999 May;8(2):119-25.
  • PMID: 12627856
    Ng HJ, Lee LH: Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy. Int J Hematol. 2003 Feb;77(2):185-7.
  • PMID: 11011806
    Breddin HK: Prophylaxis and treatment of deep-vein thrombosis. Semin Thromb Hemost. 2000;26 Suppl 1:47-52.
  • PMID: 12536351
    Haas SK: Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost. 2002 Dec;28(6):577-84.
Menampilkan 8 dari 12 artikel.

Contoh Produk & Brand

Produk: 8 • International brands: 0
Produk
  • Fraxiparine
    Solution • 9500 unit / mL • Intravenous; Subcutaneous • Canada • Approved
  • Fraxiparine
    Solution • 9500 unit / mL • Intravenous; Subcutaneous • Canada • Approved
  • Fraxiparine
    Solution • 9500 unit / mL • Intravenous; Subcutaneous • Canada • Approved
  • Fraxiparine
    Solution • 9500 unit / mL • Intravenous; Subcutaneous • Canada • Approved
  • Fraxiparine
    Solution • 9500 unit / mL • Intravenous; Subcutaneous • Canada • Approved
  • Fraxiparine Forte
    Solution • 19000 unit / mL • Intravenous; Subcutaneous • Canada • Approved
  • Fraxiparine Forte
    Solution • 19000 unit / mL • Intravenous; Subcutaneous • Canada • Approved
  • Fraxiparine Forte
    Solution • 19000 unit / mL • Intravenous; Subcutaneous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul